tbuckley/cabot-search huggingface dataset:
Brote de tricofitosis cutánea, una infección fúngica debida a Trichophyton tonsurans, en un equipo de judo de alto nivel
Authors: D. M. Poisson, Didier Rousseau, D Defo, E Estève
Journal: Eurosurveillance (2005)

Entre Octubre de 2004 y Abril de 2005 tuvo lugar un brote de 49 casos de tricofitosis cutanea producida por Trichophyton tonsurans, en un equipo de judo de alto nivel de 131 miembros en Orleans, Francia central. El equipo estaba dividido en cinco grupos: cadetes-junior varones (n=44), cadetes-junior muchachas (n=33), estudiantes universitarios varones (n=15), muchachas universitarias (n=21), y un grupo llamado “grupo tecnico”, compuesto por judokas de alto nivel que han finalizado sus estudios academicos (n=18). El brote afecto al 86 % de los cadetes-junior varones, pero solo a seis del grupo tecnico (33 %) y a cinco de los 69 miembros del resto del equipo (7 %) (cadetes-junior muchachas y estudiantes universitarios). En este articulo se describe el brote y los resultados de una encuesta que revelo un factor de riesgo conocido para el grupo tecnico: compartir una maquinilla de afeitar electrica. Se encontro que las practicas de higiene personal eran muy buenas entre el grupo de cadetes-junior varones; la alta tasa de ataque en este grupo podria estar relacionada con la deficiencia en las instalaciones de duchas en el gimnasio, lo que les llevaba a ducharse hasta varias horas despues del final del entrenamiento diario.
P1.07-017 Assessment of Cancer Immunity Status in Each Patient Using Immunogram
Authors: T. Karasaki, K. Nagayama, K. Fukumoto, K. Kitano, J. Nitadori, M. Sato, M. Anraku, A. Hosoi, H. Matsushita, K. Kakimi, J. Nakajima
Journal: Journal of Thoracic Oncology (2017)
P1.15-002 A Retrospective Study of Amrubicin Monotherapy for the Treatment of Relapsed Small Cell Lung Cancer in Elderly Patients
Authors: H. Minemura, H. Imai, T. Sugiyama, T. Tamura, K. Kaira, K. Kanazawa, H. Yokouchi, T. Kasai, T. Kaburagi, K. Minato
Journal: Journal of Thoracic Oncology (2017)
IMMU-33. CONTROLLED LOCAL EXPRESSION OF IL-12 AS GENE THERAPY CONCOMITANT WITH SYSTEMIC CHEMOTHERAPY IMPROVES SURVIVAL IN GLIOMA
Authors: John Barrett, Hongliang Cai, John Miao, Pranay Khare, Jessica Dalsing-Hernandez, Paul Gonzales, Tim Chan, Laurence Cooper, Francois Lebel
Journal: Neuro-Oncology (2017)

Successful immunotherapy is dependent on the regulation of an immune response concomitant with modulation of the tumor microenvironment. To study this hypothesis, we utilized a replication-incompetent adenovirus engineered to conditionally express mouse IL-12 (Ad-RTS-mIL-12), via our RheoSwitch Therapeutic System® (RTS®) gene switch which is tightly controlled by the oral activator ligand veledimex (V) in combination with the chemotherapeutic CCNU (lomustine, alkylating nitrosourea) in a GL-261 orthotopic glioma mouse model. The effects of Ad-RTS-mIL-12+veledimex (Ad+V) alone Ad 5x109vp+V 3-30mg/m2QDx14po or concomitantly with CCNU 9-18mg/m2QDx5ip were studied. Mice without treatment succumb to disease progression by day 39 (median 22 days). Ad+V 3mg/m2 monotherapy prolonged median overall survival (mOS) to 37 days. Eighty days after immunotherapy (end of study), ~65% mice receiving Ad +V 10-30mg/m2/day survived. CCNU 9mg/m2 failed to improve mOS while 18mg/m2 increased mOS to 36 days. Ad+V 3mg/m2 combined with CCNU 9mg/m2 failed to improve mOS while Ad+V 3mg/m2+CCNU 18mg/m2 increased survival with 60% surviving at study end. Ad+V 10mg/m2+CCNU 9mg/m2 failed to increase mOS over monotherapy while Ad+V 10mg/m2+CCNU 18mg/m2 resulted in 100% survival at end of study. Ad+V 30mg/m2+CCNU (9-18mg/m2) did not further improve survival with increased clinical signs over monotherapy that recovered on discontinuance of dosing. Ad+V increased tumor IL-12 (80 pg/mg) which was ~15-times greater than that of plasma while CCNU alone or in combination with Ad+V did not affect tumor and serum cytokines. Within the tumor, Ad+V elicited a dose-related increase in cytotoxic T cells and macrophages and decrease in regulatory T cells consistent with immune-mediated anti-tumor effects. Ad+V+CCNU did not further alter the tumor immune profile over Ad+V monotherapy. In summary, the controlled local immunostimulation with IL-12 combined with CCNU, warrants further investigation in GBM.
SurvNet@RKI – un système de déclaration électronique des maladies infectieuses
Authors: D Faensen, H Claus, J Benzler, A Ammon, T Pfoch, T Breuer, G Krause
Journal: Eurosurveillance (2006)

En 2001, un nouveau systeme de declaration electronique des maladies infectieuses a declaration obligatoire a ete mis en place en Allemagne (SurvNet@RKI). Actuellement, le systeme est utilise par les 431 centres de sante locaux (LHD, local health departments), les 16 centres federaux (SHD, state health departments) et par le Robert Koch-Institut (RKI), l’agence nationale d’epidemiologie des maladies infectieuses. Le logiciel SurvNet@RKI est ecrit en MS Access 97 et Visual Basic. Il est compatible avec MS Access ainsi qu’avec le systeme de gestion de bases de donnees MS SQL Server comme systeme de sauvegarde. La base de donnees est concue comme une base de donnee distribuee et dynamique incluant les 73 maladies a declaration obligatoire avec plus de 600 champs et environ 7000 valeurs predefinies. Un systeme integre de gestion de documents permet de supprimer, recuperer, completer et corriger les cas a tout moment et a tout niveau d’entree, ainsi que de reproduire des requetes prealablement realisees. Le systeme comprend egalement des algorithmes integres et des fonctions d’aide pour la qualite des donnees et l’application des definitions de cas. Le RKI a mis ce systeme a la disposition de tous les LHDs and SHDs gratuitement. L’institut recoit une moyenne de 300 000 notifications de cas et 6240 notifications d’epidemie par an via ce systeme. Une interface de requete accessible au public via internet, SurvStat@RKI, assure la publication rapide et exhaustive des donnees. Au cours cinq annees de fonctionnement de SurvNet@RKI dans tous les LHDs et les SHDs en Allemagne, ce systeme a montre son adequation dans le contexte complexe de la structure federale ce qui en fait un systeme particulierement interessant pour les reseaux de surveillance multinationaux. Le systeme est actuellement en cours de migration vers Microsoft C#/.NET et les formats de transport en XML. D’apres notre experience, nous formulons des recommandations pour la conception et la mise en place de systemes de surveillance electronique nationaux ou internationaux.
Delusions of Parasitosis as an Overvalent Idea
Authors: Hobart W. Walling
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Mortalidade em Portugal associada à onda de calor de Agosto de 2003: Estimação preliminar do efeito, usando um método rápido
Authors: P J Nogueira, J M Falcão, M T Contreiras, E Paixão, J Brandão, I Batista
Journal: Eurosurveillance (2005)

Durante as duas primeiras semanas de Agosto de 2003, Portugal foi afetado pela ocorrencia de uma severa onda de calor. Apos a identificacao em Portugal da influencia das ondas de calor na mortalidade em 1981 e 1991 (com excessos estimados em cerca de 1900 e 1000 obitos respectivamente), o Observatorio Nacional de Saude (ONSA) – Instituto Nacional de Saude Dr. Ricardo Jorge, em conjunto com o Centro de Vigilância, Previsao e Informacao – Instituto de Meteorologia criaram o sistema de vigilância ICARO, em pleno funcionamento desde 1999. Este sistema ICARO identifica ondas de calor com potenciais efeitos na mortalidade. Antes do final da onda de calor de 2003, o ONSA produziu uma estimacao preliminar dos efeitos sobre a mortalidade. Os resultados foram baseados no numero de obitos diarios de 1° de Junho a 12 de Agosto de 2003 e foram apresentados em 4 dias uteis. Os dados foram fornecidos por 31 Conservatorias do Registro Civil, representantes das capitais de todos os 18 distritos de Portugal Continental, e representando aproximadamente 40% da mortalidade total. O numero de obitos registrados no periodo de 30 de Julho a 12 de Agosto foi comparado com o registrado em 3 periodos de comparacao (de 2003): 1-14 de Julho, 1-28 de Julho, e 15-28 de Julho. O periodo que mais se assemelhava ao da onda de calor no tempo e nas caracteristicas, 15-28 de Julho, produziu uma estimativa de 37.7% de taxa de mortalidade acrescida ao valor esperado sob condicoes normais de temperatura. A partir deste valor, foi obtida uma estimativa de excesso de 1316 obitos para Portugal continental.
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Authors: Yelena Y. Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman, Geoffrey Y. Ku, Jamie C. Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier, Efsevia Vakiani, Jianjiong Gao, Zachary J. Heins, Benjamin E. Gross, David P. Kelsen, Liying Zhang, Vivian E. Strong, Mark Schattner, Hans Gerdes, Daniel G. Coit, Manjit Bains, Zsofia K. Stadler, Valerie W. Rusch, David R. Jones, Daniela Molena, Jinru Shia, Mark E. Robson, Marinela Capanu, Sumit Middha, Ahmet Zehir, David M. Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H. Ilson, Michael F. Berger, Laura Tang, Barry S. Taylor, David B. Solit, Nikolaus Schultz
Journal: Cancer Discovery (2017)

The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance, we implemented prospective tumor sequencing of patients with metastatic esophagogastric cancer. There was no association between homologous recombination deficiency defects and response to platinum-based chemotherapy. Patients with microsatellite instability-high tumors were intrinsically resistant to chemotherapy but more likely to achieve durable responses to immunotherapy. The single Epstein-Barr virus-positive patient achieved a durable, complete response to immunotherapy. The level of
Premiers résultats du nouveau dispositif de surveillance du VIH en France
Authors: F Lot, C Semaille, F Cazein, F Barin, R Pinget, J Pillonel, J C Desenclos
Journal: Eurosurveillance (2004)

En complement de la surveillance du Sida, les donnees sur l'infection par le VIH sont necessaires pour mieux suivre la dynamique de l'epidemie. Cet article presente les premiers resultats du systeme de declaration obligatoire et anonyme du VIH.
Ebola en Africa: descubrimientos realizados en los ultimos diez anos
Authors: R R Arthur
Journal: Eurosurveillance (2002)

La fiebre hemorragica de Ebola (FHE) ha sido reconocida por vez primera en cuatro paises en el curso de los diez ultimos anos. Los brotes registrados en esos paises y su reaparicion en otros han permitido ampliar considerablemente nuestros conocimientos sobre la epidemiologia, los aspectos clinicos, el diagnostico microbiologico y las medidas de control de la FHE. La respuesta internacional coordinada frente a algunos de los grandes brotes de FHE sirve de modelo para controlar epidemias de otras enfermedades transmisibles. Este articulo presenta una descripcion cronologica de los brotes de FHE en Africa de los ultimos diez anos, incluyendo las epidemias mas recientes de Gabon y la Republica del Congo, y presta especial atencion a los ultimos descubrimientos, subrayando algunos de los retos que aun restan por vencer.
Interrupción de la transmisión del sarampión en Gipuzkoa (País Vasco, España)
Authors: G Cilla, M Basterretxea, J Artieda, D Vicente, E Pérez-Trallero
Journal: Eurosurveillance (2004)

En Gipuzkoa (Pais Vasco, Espana) la vacunacion frente al sarampion fue introducida en 1978, siendo sustituida en 1981 por la vacunacion frente al sarampion, parotiditis y rubeola (SPR) en ninos de 12-15 meses de edad. Una segunda dosis de SPR fue introducida en 1992. Ambas dosis fueron bien aceptadas por la poblacion y consiguieron coberturas elevadas (95% y 91% para la primera y segunda dosis respectivamente en el periodo 1993-2002). La circulacion del virus del sarampion fue interrumpida en la segunda mitad de los 90, no habiendose declarado casos de sarampion indigena entre 1998 y 2003, habiendose confirmado durante este periodo solo casos importados. Estos datos indican que el programa de vacunacion frente al sarampion ha sido eficaz. No obstante, para evitar brotes de sarampion a partir de reintroducciones del virus, es preciso mantener una cobertura vacunal elevada (g95%) en ambas dosis de SPR.
ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)
Authors: Daniela Bota, Warren Mason, Santosh Kesari, David Piccioni, Dawit Aregawi, Annick Desjardins, Benjamin Winograd, Steven D Reich, Nancy Levin, Mohit Trikha
Journal: Neuro-Oncology (2017)

Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a novel therapeutic strategy for ndGBM. MRZ -- an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma preclinical activity -- is being evaluated in ndGBM patients (NCT02903069). The phase 1 study (MRZ at 0.55, 0.7, 0.8, 1.0, and 1.2 mg/m2) is accruing in separate concomitant (MRZ+TMZ+RT) and adjuvant (MRZ+RT) treatment cohorts (3 + 3 design), followed by dose-expansion at the recommended phase 2 dose in concomitant followed by adjuvant treatment cohorts. Concomitant treatment (42 days (D)): MRZ (10 min IV infusion) D1, 8, 15, 29, 36; RT total dose 60 Gy; TMZ (75 mg/m2, PO QD). Adjuvant treatment (28D-cycle): MRZ D1, 8, 15; TMZ (150–200 mg/m2, PO QDX5). Tumor response (RANO criteria) measured at beginning and end of concomitant treatment, and every other cycle during adjuvant treatment; MRZ and TMZ PK in concomitant treatment D1-2, 8–9. Mean age 55 yrs (60% male) for 20 patients in 14Apr2017 interim analysis (cohorts 1–3 have completed accrual in concomitant treatment, cohorts 1 and 2 have completed accrual and 2 patients are enrolled in adjuvant cohort 3); one DLT (fatigue) in the 0.7 mg/m2 adjuvant cohort. Most common treatment-related AEs (≥4 pts): fatigue, nausea, vomiting, decreased appetite, dizziness, hallucination; three Grade 3 SAEs (fatigue, hallucination, vomiting; all MRZ-related); two Grade 2 SAEs (nausea, confusional state, MRZ-related). Seventeen of the 20 patients included in this interim analysis remain on study: 7 of 9 concomitant patients are continuing in adjuvant treatment (longest beginning adjuvant cycle 7); of 11 adjuvant pts, two beginning cycle 9. The study is ongoing at 1.0 mg/m2 for both concomitant and adjuvant dose-escalation cohorts. Together the data demonstrate that the combination of MRZ with standard of care in ndGBM is well tolerated and may provide novel therapeutic benefit in this unmet need.
ACTR-55. TUMOR TREATING FIELDS WITH SECOND LINE TREATMENT COMPARED TO SECOND LINE TREATMENT ALONE IN PATIENTS AT FIRST RECURRENCE OF GLIOBLASTOMA – A POST HOC ANALYSIS OF THE EF-14 PHASE 3 CLINICAL TRIAL
Authors: Santosh Kesari, David Tran, William Read, Manmeet Ahluwalia, John Villano, Steven Toms, Jay-Jiguang Zhu, Zvi Ram
Journal: Neuro-Oncology (2017)

The EF14 phase 3 trial tested the efficacy of tumor treating fields with temozolomide (TTFields/TMZ) compared to TMZ alone in newly diagnosed glioblastoma. The trial design allowed for patients in both arms to continue treatment until second progression, 24 months or unacceptable toxicity. Patients on TTFields/TMZ were allowed to continue TTFields with second- line therapies. After enrollment of all 695 patients, 26 TMZ alone patients crossed over to receive TTFields prior to disease progression based on the positive interim analysis results. Here we compared the outcomes of all EF14 patients on TTFields with second line therapies (n=336) to those who received second line therapy alone (n=112). No significant differences were seen in second-line treatments between groups; numerically more patients in the control group versus TTFields group received bevacizumab (49% vs 33%), chemotherapy (84% vs 55%) or additional radiotherapy (19% vs 9%). This may be attributed to the shorter treatment duration prior to disease progression in control patients. About one quarter of patients on both arms had additional surgery at progression and 28% of TTFields patients continued on that treatment alone after recurrence. Baseline characteristics were well balanced with no statistically significant differences found between groups. Adverse event profile was consistent with the entire study analysis. Overall survival from progression was significantly longer in the TTFields group compared to the control group (median 12.0 months versus 10.8 months; hazard ratio 0.75, 95%CI 0.59–0.94, log rank p=0.038). We conclude that the continuation of TTFields with second line treatment beyond first progression in newly diagnosed glioblastoma is associated with longer survival from the time of recurrence compared to patients who receive TMZ followed by second line treatments. Whether this finding is true also in patients who start TTFields at first recurrence together with second line therapies needs to be tested in prospective trials.
SURG-13. GENOMIC ANALYSIS, SURGICAL TREATMENT AND OUTCOMES OF LOWER-GRADE GLIOMAS IN A SINGLE INSTITUTION
Authors: David Eagle, Anca Merla, Fiona McKevitt, Susan Clenton, Caroline Bridgewater, Stephen Wharton, Hesham Zaki, David Jellinek, Shungu Ushewokunze
Journal: Neuro-Oncology (2017)

Recent research has demonstrated that IDH and 1p/19q status in lower grade gliomas better predicts clinical outcome than histological class. We reviewed our institutional outcomes based on these parameters combined with the extent of surgical resection and adjuvant treatment given. DESIGN: A 10-year retrospective case review. SUBJECTS: Patients undergoing biopsy or resection of lower-grade gliomas between 2005 and 2016 in our institution. 122 patients underwent biopsy or resection of a tumour on which genetic analysis was performed. 42 underwent a gross total resection (GTR), 72 received radiotherapy within 3 months of surgery and 28 received chemotherapy within 3 months of surgery. Those with IDH1 wildtype had a significantly increased risk of disease progression (coef 0.8019, p-value 0.0129) and of death (coef 1.21, p-value 0.0024), while those with 1p19q co-deletion and IDH1 mutation had a significantly reduced risk of disease progression (coef -2.4823, p-value 0.0157). Across all tumours, GTR significantly reduced the risk of disease progression (coef -0.8277, p-value 0.0073) and of death (coef -1.2029, p-value 0.0052) while radiotherapy significantly reduced the risk of death (coef -0.6789, p-value 0.0446) only. Our outcomes based on genomic analysis are now more predictable than with the previous histological classification and are consistent with other published data. GTR and radiotherapy have been demonstrated to play a significant role in management. The ongoing review of treatment outcomes with respect to genomic classification will further inform the surgical and adjuvant management for all lower-grade glioma subtypes in the future.
Seis anos de vigilância das hepatites A e B na clínica geral, em França
Authors: A Flahault, P Maison, N Farran, V Massari
Journal: Eurosurveillance (1997)

A rede  Sentinela francesa e composta por medicos generalistas que registam de forma continua os casos respeitantes a sete doencas transmissiveis (os sindromas gripais, a diarreia aguda, a varicela, a parotidite, o sarampo, a uretrite e as hepatites agudas de provavel origem viral) e as prescricoes de serologia para o HIV. Este sistema de vigilância permite monitorizar continuamente a incidencia das infeccoes pelos virus A e B da Hepatite (VHA e VHB) no territorio metropolitano frances.
La légionellose en Europe en 2003-2004
Authors: K D Ricketts, C Joseph
Journal: Eurosurveillance (2005)

Une fois par an, les pays collaborateurs du Groupe de travail europeen pour la surveillance de la legionellose associee aux voyages (EWGLINET) doivent fournir une serie de donnees portant sur des informations epidemiologiques et microbiologiques des cas de legionellose (infections nosocomiales, communautaires ou associees aux voyages) detectes dans leur pays dans l’annee en cours. Cet article presente les donnees recueillies pour 2003 et 2004. Au cours de cette periode, 9166 cas ont ete declares dans les series de donnees de 35 pays, dont 941 cas associes a des epidemies. Quatorze pays ont rapporte un total de 218 epidemies detectees. Le taux d’infection variait d’un pays a l’autre, allant de 28,7% a moins de un cas par million d’habitants. Ces informations sont importantes car elles permettent aux pays d’evaluer l’efficacite de leur programme de surveillance national quant a la detection des cas. 
Au cours des deux annees, le deces a ete rapporte pour 748 cas, soit un taux de mortalite de 8,2%. Le manque d’informations epidemiologiques detaillees sur les deces dus a la legionellose est evident. La creation du Centre europeen pour le controle et la prevention des maladies est l’opportunite de developper des collaborations europeennes plus fortes et d’ameliorer la protection face aux epidemies de legionellose des Europeens.
Abstract 20251: Aortic Valve Calcification and Coronary Plaque Morphology in Japanese Heterozygous Familial Hypercholesterolemia Patients With Gene Mutation
Authors: Aya Yamamoto, Akiko Sakai, Haruki Sekiguchi, Kayoko Sato, Kenji Fukushima, Syuji Sakai, Nobuhisa Hagiwara
Journal: Circulation (2017)

Introduction:  Heterozygous familial hypercholesterolemia (hFH) is the most common genetic disease and leading cause of premature cardiovascular disease (CVD). hFH is caused by mutations of FH genes such as LDL-receptor (LDLR), apolipoprotein B-100 (APOB), proprotein convertase subtilisin / kexin type 9 (PCSK9), or low-density lipoprotein receptor adapter protein 1 (LDLRAP1). On the other hand, aortic valve calcification (AVC) is associated with an elevated risk of cardiovascular events.   Objectives:  To investigate the association between AVC and coronary plaque morphology related with gene mutation.   Methods:  We enrolled 39 patients with clinical hFH, diagnosed according to FH guidelines of Japanese Atherosclerosis Society (median age, 57.2±2.0 years; men 64%) and 32 patients with DL (median age, 64.8±2.2 years; men 63%). We evaluated all patients underwent 320-slice coronary CT, AVC score, ABI and PWV for the assessment of atherosclerosis. The genotypes of 44 patients were analyzed using an Illumina Mi-seq sequencer.   Results:  AVC was detected more frequently in patients with hFH than in patients with DL (76% and 56%, p   Conclusions:  The AVC is developed in hFH patients, and the AVC is related to coronary plaque morphology. hFH patients with LDLR mutation or PCSK9 mutation had higher AVC. The genetic diagnosis is important to assess coronary plaque morphology and to prevent the future CVD incidence in FH patients.